metricas
covid
Buscar en
Annals of Hepatology
Toda la web
Inicio Annals of Hepatology Real-World Effectiveness of Direct-Acting Antiviral Regimens against Hepatitis C...
Journal Information
Vol. 23.
(July - August 2021)
Share
Share
Download PDF
More article options
Visits
2090
Vol. 23.
(July - August 2021)
Concise reviews
Open Access
Real-World Effectiveness of Direct-Acting Antiviral Regimens against Hepatitis C Virus (HCV) Genotype 3 Infection: A Systematic Review and Meta-Analysis
Visits
2090
Liwei Zhuanga,c, Junnan Lib,c, Yu Zhanga, Shibo Jia, Yue Lia, Yingying Zhaoa, Ben Lia, Wei Lia, Min Quana, Ying Duana, Hong Zhaoa, Danying Chenga, Xiaomei Wanga,c, Weini Oua,c, Huichun Xinga,c,
Corresponding author
hchxing@sohu.com
hchxing@ccmu.edu.com

Corresponding author at: Department of Hepatology Division 3, Beijing Ditan Hospital, Capital Medical University8 Jingshundong Street, Chaoyang District Beijing, 100015, China; Peking University Ditan Teaching Hospital, Beijing, China.
a Center of Liver Disease Division 3, Beijing Ditan Hospital, Capital Medical University, Beijing, China
b Department of Science and Education, Beijing Ditan Hospital, Capital Medical University, Beijing, China
c Peking University Ditan Teaching Hospital, Beijing, China
This item has received

Under a Creative Commons license
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (4)
Show moreShow less
Abstract

Patients with hepatitis C virus (HCV) genotype 3 (GT3) infection are resistant to direct-acting antiviral (DAA) treatments. This study aimed to analyze the effectiveness of sofosbuvir (SOF)+daclatasvir (DCV) ± ribavirin (RBV); SOF+velpatasvir (VEL)±RBV; SOF+VEL+voxilaprevir (VOX); and glecaprevir (GLE)+pibrentasvir (PIB) in the treatment of HCV GT3-infected patients in real-world studies.

Articles were identified by searching the PubMed, EMBASE, and Cochrane Library databases from January 1, 2016 to September 10, 2019. The meta-analysis was conducted to determine the sustained virologic response (SVR) rate, using R 3.6.2 software.

Thirty-four studies, conducted on a total of 7328 patients from 22 countries, met the inclusion criteria. The pooled SVR rate after 12/24 weeks of treatment was 92.07% (95% CI: 90.39–93.61%) for the evaluated regimens. Also, the SVR rate was 91.17% (95% CI: 89.23–92.94%) in patients treated with SOF+DCV±RBV; 95.08% (95% CI: 90.88–98.13%) in patients treated with SOF+VEL±RBV; 84.97% (95% CI: 73.32–93.91%) in patients treated with SOF+VEL+VOX; and 98.54% (95% CI: 96.40–99.82%) in patients treated with GLE+PIB. The pooled SVR rate of the four regimens was 95.24% (95% CI: 93.50–96.75%) in non-cirrhotic patients and 89.39% (95% CI: 86.07–92.33%) in cirrhotic patients. The pooled SVR rate was 94.41% (95% CI: 92.02–96.42%) in treatment-naive patients and 87.98% (95% CI: 84.31–91.25%) in treatment-experienced patients.

The SVR rate of GLE+PIB was higher than other regimens. SOF+VEL+VOX can be used as a treatment regimen following DAA treatment failure.

Keywords:
Direct-acting antiviral
Effectiveness
Real-world
Genotype 3 HCV
Abbreviations:
DAA
DCV
EMA
FDA
GLE
HCV
PIB
RBV
RASs
SOF
SVR
VEL
VOX
WHO
Full Text
1Introduction

According to the reports of the World Health Organization (WHO), up to 71 million people were infected with the hepatitis C virus (HCV) around the world in 2015 [1]. The high rate of viral replication and mismatch in the process of replication leads to frequent viral mutations. The antiviral treatment regimen in the interferon era mainly included pegylated interferon, combined with ribavirin. However, this regimen had a low sustained virologic response (SVR) and was associated with more drug-related adverse events. With the clinical application of direct-acting antivirals (DAAs), the SVR rate significantly improved, and toxicity declined. However, previous studies have reported that the antiviral effectiveness of DAAs varies per genotype.

The SVR rate of HCV genotype 3 (GT3) infection is relatively lower than that of other genotypes. In recent years, considerable progress has been made in the antiviral treatment of HCV-GT3 infection, using new drug regimens and drug combinations. The United States Food and Drug Administration (FDA) and the European Medicine Agency (EMA) approved the regimens, containing sofosbuvir (SOF)+daclatasvir (DCV)±ribavirin (RBV) in 2015 and SOF+velpatasvir (VEL)±RBV in 2016 for the treatment of HCV-GT3 infection. They also approved SOF+VEL+voxilaprevir (VOX), as well as glecaprevir (GLE)+pibrentasvir (PIB), in 2017 [2].

In this meta-analysis, we systematically evaluated the pooled SVR rates of DAA regimens against HCV-GT3 infection in real-world studies.

2Materials and methods2.1Literature search strategy

The following terms were used to search PubMed, EMBASE, and Cochrane Library from January 1, 2016 to September 10, 2019: [“sofosbuvir” AND “daclatasvir” OR “Sovaldi”] OR [“sofosbuvir” AND “velpatasvir” OR “Epclusa”] OR [“sofosbuvir” AND “velpatasvir” AND “voxilaprevir” OR “Vosevi”] OR [“glecaprevir” AND “pibrentasvir” OR “Mavyret”].

2.2Inclusion and exclusion criteria

Two researchers (ZLW and ZY) scanned the titles and abstracts of the papers independently and assessed eligible trials, according to the inclusion criteria. Articles, which were potentially suitable based on the inclusion criteria, were extracted for a full-text review. Any disagreements were resolved by discussion. The inclusion criteria for the articles were as follows: subject (assessment of patients with chronic HCV infection); intervention (SOF+DCV, SOF+VEL, SOF+VEL+VOX, or GLE+PIB); primary outcomes (SVR rate after 12/24 weeks); and study design (real-world studies). On the other hand, the exclusion criteria were as follows: 1) unavailability of valid data related to HCV-GT3 infection; 2) inclusion of less than 10 patients in the study during treatment or follow-up for effectiveness evaluation; and 3) summaries, case reports, or meta-analyses.

2.3Data extraction

Two authors (ZLW and ZY) read the full-text of articles independently. The information extracted from the articles included the demographics, main clinical characteristics of the patients, resistance-associated substitutions (RASs), average HCV RNA concentration at baseline, treatment regimen, drug dosage, therapy duration, SVR12/24, and virologic failure. Also, the authors resolved discrepancies by consultation with a third party (XHC).

2.4Data analysis

Meta-analyses were conducted to determine the pooled SVR rate in all populations and subgroups, using the Freeman-Tukey double arcsine transformation in a random-effects model. Chi-square test was performed to compare the SVR rates of multiple groups. Also, Egger's test was conducted for evaluating potential publication bias. All analyses were performed in R 3.6.2 software with a meta package.

3Results3.1Main characteristics of the studies and populations

A total of 7328 HCV GT3-infected patients were examined in 34 studies, which were selected among 5525 screened articles (Fig. 1). The studies were conducted in 22 countries: Germany (n=6), Brazil (n=4), USA (n=3), France (n=3), India (n=3), Italy (n=3), Pakistan (n=3), Spain (n=3), China (n=2), Myanmar (n=2), Norway (n=2), Sweden (n=2), Argentina(n=1), Austria(n=1), Denmark(n=1), UK(n=1), Finland(n=1), Ireland(n=1), Malaysia(n=1), Netherlands(n=1), Singapore(n=1), and Thailand (n=1). In 34 studies, there were 37 treatment regimens, of which 73% were SOF+DCV±RBV (27/37, 73%), followed by SOF+VEL±RBV (5/37, 14%), SOF+VEL+VOX (3/37, 8%), and GLE+PIB (2/37, 5%), respectively. The total number of patients included is 7328, 4701 patients were treated with SOF+DCV±RBV (4701/7328, 64%), followed by SOF+VEL±RBV (2266/7328, 31%), GLE+PIB (244/7328, 3%) and SOF+VEL+VOX (117/7328, 2%), respectively.

Fig. 1.

The flowchart of article selection.

(0.32MB).

A summary of the demographic and clinical characteristics of the patients is presented in Table 1. Patients with chronic HCV-GT3 infection, included in these real-world studies, also had diseases, such as hepatitis and decompensated cirrhosis. Some of these patients had refractory comorbidities, such as hepatocellular carcinoma (HCC), HIV/HBV co-infection, renal failure, history of liver transplantation, and history of DAA treatment failure.

Table 1.

The main characteristics of studies included in the meta-analysis.

Study  Year  Country  Main clinical characteristics of the patients  Resistance-associated substitutions  Mean age  Sex (male/ female)  Mean HCV RNA at baseline (log10 IU/mL)  No. of patients  Regimen and dosage  Treatment duration (weeks)  SVR12/24 (n)  Virologic failurea(n) 
Sarwar et al. [32019  Pakistan  treatment experienced or with advanced fibrosis added RBV; with cirrhosis for 24 weeks; 58.4% with cirrhosis; 27.4% treatment experienced  NA  NA  NA  6.34  113  SOF (400mg)+DCV (60mg)±RBV  12-24  102  NA 
Pariente et al. [42019  France  59.0% with cirrhosis  NA  NA  NA  NA  117  SOF (400mg)+DCV (60mg)±RBV  12-24  103  NA 
Mangia et al. [52019  Italy  all with cirrhosis and portal hypertension, 54.1% transient elastography results >20KPa; 72.8% treatment naïve; 5.3% with HCC; 9.8% HIV positive; 14.6% past intravenous drug use; 18.5% alcohol abuse; 17.6% with diabetes  NA  52.9  175/30  2.53±4.3  205  SOF (400mg)+VEL (100mg)  12  200  5 relapses 
Macken et al. [62019  England  91% with cirrhosis, 63.3% treatment naive  NA  NA  NA  NA  256  SOF (400mg)+DCV (60mg)±RBV  12  216   
Lobato et al. [72019  Brazil  NA  NA  NA  NA  NA  817  SOF (400mg)+DCV (60mg)  12-24  736  NA 
Llaneras et al. [82019  Spain  all received a DAA-based interferon-free regimen: SOF and DCV or VEL or LDV; 43.3% with cirrhosis  of 6 relapses 1 detected with L28S, M31L and D168G, 1 with Y93H, 2 not detected, 2 NA  NA  NA  NA  30  SOF (400mg)+VEL (100mg)+VOX (100mg)  12  24  6 relapses 
Hlaing et al. [9]2019Myanmar6.16% treatment experienced; 67.6% with cirrhosis or advanced fibrosis  NA  NANANA193  SOF (400mg)+DCV (60mg)±RBV  12-24  187  6 relapses 
    83  SOF (400mg)+VEL (100mg)±RBV  12-24  75  8 relapses 
Han et al. [102019  China  62.5% with history of drug abuse; 25% with compensated cirrhosis; 9.4% renal impairment; 96.9% treatment naive  NA  44.26  26/6  5.91  32  SOF (400mg)+DCV (60mg)±RBV  12-24  31  1 relapse 
Goel et al. [112019  India  all eGFR<30ml/min, 18.2% with cirrhosis;  NA  NA  NA  NA  22  SOF (200mg)+DCV (60mg)  12  19 
Degasperi et al. [122019  Italy  all with a prior DAA failure: SOF and VEL or LDV, or OBV/PTV-r+DSV  of 3 relapses 1 detected with Y93H, 2 NA  NA  NA  NA  42  SOF (400mg)+VEL (100mg)+VOX (100mg)±RBV  12  33  3 relapses 
D'Ambrosio et al. [132019  Italy  NA  of 2 relapses 1 detected with Y93H and L31I  NA  NA  NA  68  GLE (300mg)+PIB (120mg)  8-16  66  2 relapses 
Butt et al. [142019  Pakistan  84.2% treatment naïve, 52.5% with cirrhosis,  NA  47.06  33/68  NA  101  SOF (400mg)+DCV (60mg)±RBV  24  96  NA 
Berg et al. [152019  Germany  8 weeks for treatment-naïve and non-cirrhotic patients, 12 weeks for treatment-naïve and cirrhotic patients, 16 weeks for treatment-experienced patients  NA  NA  NA  NA  176  GLE (300mg)+PIB (120mg)  8-16  174  NA 
Belperio et al. [16]2019USA42.1% with cirrhosis, 3.03% with HCC, 22.9% treatment experienced  NA  58.95  868/23  6.05  891  SOF (400mg)+DCV (60mg)±RBV  12-16  796  NA 
26.5% with cirrhosis, 2.42% with HCC, 9.7% treatment experienced    58.95  1662/73  6.05  1735  SOF (400mg)+VEL (100mg)±RBV  12-24  1573  NA 
Belperio et al. [172019  USA  all treatment experienced: SOF and DCV or VEL or LDV, 51.1% with cirrhosis, 4.44% with HCC, 2.22% with HIV coinfected, 37.8% with diabetes  NA  59.7  51/0  6.1  45  SOF (400mg)+VEL (100mg)+VOX (100mg)  12  42  NA 
Araujo et al. [182019  Brazil  6.5% with cirrhosis  NA  NA  NA  NA  31  SOF (400mg)+DCV (60mg)  12  30  1 virologic failure 
Wehmeyer et al. [192018  Germany  28.75% treatment experienced, 33.75% with cirrhosis, 15% with HIV coinfected  NA  NA  NA  NA  80  SOF (400mg)+DCV (60mg)±RBV  12-24  76  NA 
Felden et al. [202018  Germany  24.8% treatment experienced, 26.6% with cirrhosis, 8.56% with HIV coinfected  22 patients with baseline NS5A RASs (Y93H, A30K or L31M)  NA  NA  NA  222  SOF (400mg)+VEL (100mg)±RBV  12  213  NA 
Tao et al. [21]2018China34.6% with cirrhosis  NA  41.71  48/33  6.30  81  SOF (400mg)+DCV (60mg)±RBV  12-24  71  10 relapses 
23.8% with cirrhosis    37.38  13/8  6.04  21  SOF (400mg)+VEL (100mg)  12-24  21 
Mucenic et al. [222018  Brazil  all liver transplant recipients  NA  NA  NA  NA  26  SOF (400mg)+DCV (60mg)±RBV  12  22  2 relapses and 2 non-responses 
Minguez et al. [232018  Spain  all HIV-coinfected  NA  NA  NA  NA  53  SOF (400mg)+DCV (60mg)±RBV  12  48   
Mehta et al. [242018  India  NA  NA  NA  NA  NA  372  SOF (400mg)+DCV (60mg)±RBV  12-24  362  5 non-responses, 2 breakthroughs, and 10 relapses 
Marciano et al. [252018  Argentina  89.4% with cirrhosis,  NA  NA  NA  NA  47  SOF (400mg)+DCV (60mg)±RBV  24  38  NA 
Lim et al. [262018  India, Myanmar, Pakistan, Thailand, Singapore, and Malaysia  NA  NA  NA  NA  NA  310  SOF (400mg)+DCV (60mg)±RBV  12-24  282 
Kwo et al. [272018  USA  64% liver transplant, 36% with decompensated cirrhosis  NA  NA  NA  NA  25  SOF (400mg)+DCV (60mg)±RBV  24  22  1 breakthrough 
Rockstroh et al. [282017  Germany  all HIV-coinfected and with an advanced stage of cirrhosis  NA  NA  NA  NA  13  SOF (400mg)+DCV (60mg)±RBV  24  12  NA 
Lacombe et al. [292017  France  all HIV-coinfected and with advanced liver disease  NA  NA  NA  NA  47  SOF (400mg)+DCV (60mg)±RBV  12-24  42  2 relapses and 1 undefined virologic failure 
Hezode et al. [302017  France  76.9% with cirrhosis, 8.1% with HCC, 9.0% post-liver transplant HCV recurrence, 9.0% pre-liver/renal transplant, 71.2% treatment experienced, 14.1% HIV-coinfected, 2.1% HBV-coinfected  NA  54.2  245/88  6.0  333  SOF (400mg)+DCV (60mg)±RBV  12-24  278  4 breakthroughs, 32 relapses, and 9 undefined 
Dalgard et al. [312017  Denmark, Sweden, Norway, and Finland  51.8% treatment experienced, 73.2% with cirrhosis  NA  56  135/60  NA  193  SOF (400mg)+DCV (60mg)±RBV  12-24  177  NA 
Cornberg et al. [322017  Germany  32.7% with cirrhosis, 29.1% treatment experienced  NA  NA  NA  NA  220  SOF (400mg)+DCV (60mg)±RBV  12-24  207  NA 
Gray et al. [332017  Ireland  28.9% treatment experienced  NA  NA  NA  NA  76  SOF (400mg)+DCV (60mg)±RBV  24  67 
Sette-Jr et al. [342017  Brazil  35.7% with cirrhosis  of 4 relapses 2 detected with Y93H, 2 not done  NA  NA  NA  28  SOF (400mg)+DCV (60mg)±RBV  12-24  24  4 relapses 
Alonso et al. [352017  Spain  26% with decompensated cirrhosis, 45% treatment experienced  NA  55  110/21  6.0  131  SOF (400mg)+DCV (60mg)±RBV  12-24  123  6 relapses, 1 breakthrough 
Welzel et al. [362016  Germany, Austria, Netherlands, Sweden, and Norway  84.9% with cirrhosis, 60.2% treatment experienced  NA  NA  NA  NA  93  SOF (400mg)+DCV (60mg)±RBV  24  82  NA 

NA: Data not available for HCV GT3-infected patients; DSV: Dasabuvir; LDV: Ledipasvir; OBV/PTV-r: Ombitasvir/paritaprevir-ritonavir; VEL: Velpatasvir.

a

Relapse or breakthrough or undefined virologic failure.

3.2Pooled SVR rate for all patients

A total of 7328 patients with HCV-GT3 infection were treated with SOF+VEL+VOX, SOF+DCV±RBV, SOF+VEL±RBV, and GLE+PIB. The pooled SVR12/24 rate was 92.07% (95% CI: 90.39–93.61%), as shown in Fig. 2. The SVR12/24 rate was 84.97% (95% CI: 73.32–93.91%) in patients treated with SOF+VEL+VOX; 91.17% (95% CI: 89.23–92.94%) in patients treated with SOF+DCV±RBV; 95.08% (95% CI: 90.88–98.13%) in patients treated with SOF+VEL±RBV; and 98.54% (95% CI: 96.40–99.82%) in patients treated with GLE+PIB.

Fig. 2.

The forest plots of pooled SVR rates for all patients.

(0.97MB).

The results of Chi-square test indicated a significant difference in the SVR of four treatment regimens (P<0.001). The two-by-two comparisons showed that GLE+PIB was superior to the other three regimens. The SOF+VEL±RBV regimen was superior to SOF+VEL+VOX, which could be related to the selection of populations with a history of DAA (SOF+VEL or LDV or DCV or OBV/PTV-r+DSV) treatment failure in the SOF+VEL+VOX group. However, there was no significant difference between SOF+DCV±RBV and SOF+VEL±RBV or between SOF+DCV±RBV and SOF+VEL+VOX.

3.3Stratification analysis (non-cirrhotic patients)

According to the subgroup analysis of non-cirrhotic patients, the pooled SVR12/24 rate was 95.24% (95% CI: 93.50–96.75%) in patients treated with SOF+DCV±RBV, SOF+VEL+VOX, and SOF+VEL±RBV, as shown in Fig. 3A. The SVR12/24 rate was 95.36% (95% CI: 93.02–97.31%) in patients treated with SOF+DCV±RBV; and 94.61% (95% CI: 89.78–98.00%) in patients treated with SOF+VEL±RBV.

Fig. 3.

The forest plots of stratification analysis. (A) The forest plots of SVR rates in non-cirrhotic patients. (B) The forest plots of SVR rates in cirrhotic patients. (C) The forest plots of SVR rates in treatment-naive patients. (D) The forest plots of SVR rates in treatment-experienced patients.

(0.92MB).
3.4Stratification analysis (cirrhotic patients)

The pooled SVR12/24 rate was 89.39% (95% CI: 86.07–92.33%) in cirrhotic patients treated with SOF+DCV±RBV, SOF+VEL+VOX, and SOF+VEL±RBV, as shown in Fig. 3B. Based on the results, the SVR12/24 rate was 88.72% (95% CI: 85.19–91.86%) in patients treated with SOF+DCV±RBV; and 92.73% (95% CI: 81.85–99.03%) in patients treated with SOF+VEL±RBV.

3.5Stratification analysis (treatment-naive patients)

According to the subgroup analysis of treatment-naive patients, the pooled SVR12/24 rate in patients treated with SOF+DCV±RBV and SOF+VEL±RBV was 94.41% (95% CI: 92.02–96.42%), as shown in Fig. 3C. Also, the SVR rates in patients treated with SOF+DCV±RBV and SOF+VEL±RBV were 93.77% (95% CI: 90.15–96.65%) and 95.68% (95% CI: 90.73–98.87%), respectively.

3.6Stratification analysis (treatment-experienced patients)

The pooled SVR12/24 rate of treatment-experienced patients with HCV-GT3 infection, treated with SOF+VEL+VOX, SOF+VEL±RBV, and SOF+DCV±RBV, was 87.98% (95% CI: 84.31–91.25%), as shown in Fig. 3D. Also, the corresponding SVR12/24 rates were 87.90% (95% CI: 72.16–98.02%), 90.24% (95% CI: 78.42–97.89%), and 86.25% (95% CI: 82.85–89.36%), respectively.

3.7Sensitivity analysis of heterogeneity

Changes in the results of sensitivity analysis ranged from 91.75% to 92.39% after excluding articles one by one, which is a very small range, indicating stable results.

3.8Publication bias

The results of Egger’s test indicated no publication bias (t=0.12404, DF=35, P=0.902), as shown in Fig. 4.

Fig. 4.

The funnel plot.

(0.06MB).
4Discussion

In this review, the majority of treatment regimens in real-world studies included SOF+DCV±RBV, which accounted for 73% of treatments. The SOF+DCV±RBV regimen was the first-line therapeutic regimen for all HCV genotypes, as recommended by the FDA and EMA. In our meta-analysis, the pooled SVR12/24 was 91.17% in HCV GT3-infected patients. The SVR rates of cirrhotic and non-cirrhotic patients were 88.72% and 95.36%, respectively. Also, the SVR rates of treatment-experienced and treatment-naive patients were 86.25% and 93.77%, respectively.

The cirrhosis stage and history of treatment had significant effects on the antiviral effectiveness. In this regard, a phase III clinical study (ALLY-3) [37] showed that the pooled SVR12 rate of HCV GT3-infected patients, treated with SOF+DCV, was 89%, of which there was 63% in patients with cirrhosis and 96% in patients without cirrhosis; therefore, the SOF+DCV regimen was not suitable for cirrhotic and treatment-experienced patients with HCV-GT3 infection. Also, Amit Goel et al. [11] evaluated patients with renal insufficiency (eGFR<30ml/min), treated with SOF (200mg per day), and reported an SVR12 rate of 86.36%. Moreover, Mucenic et al. [22] selected patients with virologic relapse following liver transplantation and reported an SVR12 rate of 84.62%. Also, Carlos Minguez [23], Jurgen K Rockstroh [28], and Karine Lacombe [29] in studies on HIV co-infected patients reported SVR rates of 90.57%, 92.31%, and 89.36%, respectively. Compared to renal insufficiency and virologic relapse following liver transplantation, the effect of HIV co-infection on the antiviral effectiveness of SOF+DCV±RBV was relatively less significant.

The SOF+VEL±RBV regimen, approved in 2017, is the first treatment regimen, which can be used for 12 weeks, regardless of HCV genotype and liver fibrosis stage. In the present study, the SVR rate of patients with HCV-GT3 infection was 95.08%, which is higher than that of SOF+DCV±RBV. The SVR rates of cirrhotic, non-cirrhotic, treatment-naive, and treatment-experienced patients, treated with SOF+VEL±RBV, were 92.73%, 94.61%, 95.68%, and 90.24%, respectively. The effect of treatment history on the antiviral effectiveness of SOF+VEL±RBV was more significant than that of cirrhosis stage.

Belperio et al [16] gained the similar SVR rates of the GT3 HCV patients treated with SOF+VEL±RBV compared with SOF+DCV±RBV. In this meta-analysis the pooled SVR rate of SOF+VEL±RBV was a little higher (95.08%) than that of SOF+DCV±RBV (91.17%). This may be associated with the high SVR rate (100%, 21/21) from Tao’s study [21]. In non-cirrhotic patients, the SVR rates of the two regimens were almost the same (94.61% for SOF+VEL±RBV and 95.36% for SOF+DCV±RBV). However, in patients with cirrhosis, the SVR rate of SOF+VEL±RBV was higher than that of SOF+DCV±RBV (92.73% and 88.72%, respectively). Also, in cirrhotic patients, the SOF+VEL±RBV regimen was found to be more suitable than SOF+DCV±RBV.

The GLE+PIB regimen was approved by the FDA and EMA, regardless of HCV genotypes. This regimen decreases the treatment duration to eight weeks for hepatitis and compensated cirrhotic patients. It can be also used for patients with renal dysfunction or even those undergoing dialysis. In a phase-III clinical study (ENDURANCE-3) [38] on patients treated with GLE+PIB for 8 or 12 weeks, the SVR rate was 95% in treatment-naive hepatitis patients with HCV-GT3 infection. Also, in the SURVEYOR-II Part-3 study [39], the SVR rate of HCV GT3-infected patients was 91% after 12 weeks of treatment; the patients were either treatment-naive or treatment-experienced, with or without cirrhosis. Moreover, in the EXPEDITION-2,4 studies [40,41], the SVR rate was 98% in patients after 8-12 weeks of treatment. In this real-world meta-analysis, the SVR rate of patients with HCV-GT3 infection, treated with GLE+PIB, could reach 97% or higher.

Our meta-analysis showed that the SVR rate of SOF+VEL+VOX was 84.97%, which is lower than that of SOF+DCV±RBV, SOF+VEL±RBV, and GLE+PIB; this result may be related to previous resistance to DAA (SOF+VEL or LDV or DCV or OBV/PTV-r+DSV) in patients treated with SOF+VEL+VOX. The SOF+VEL+VOX regimen, which included a combination of three DAAs, was mainly designed as a treatment plan for patients with a history of DAA treatment failure. In this regard, the POLARIS-3 study [42] evaluated patients with liver cirrhosis, who were initially treated with DAAs. After eight weeks of treatment with SOF+VEL+VOX, the SVR rate of patients with HCV-GT3 infection reached 96% (106/110).

Moreover, in the POLARIS-1 study [43], the SVR rate of patients with HCV-GT3 infection was 95% (74/78) after 12 weeks of treatment. In this paper, some real-world studies [8,12,17] on patients with a history of DAA treatment failure reported SVR rates of 80.00%, 78.57%, and 93.33%, respectively. The antiviral effectiveness of SOF+VEL+VOX in real-word studies was lower than that of registered clinical studies in patients with a history of DAA treatment failure. Also, in two real-word studies [8,12], the number of patients with virologic relapse was 6/30 and 3/42 during the follow-up, respectively.

In real-world studies, the SVR rate of SOF+VEL+VOX was low in HCV GT3-infected patients with a history of DAA treatment failure, and the possibility of virologic relapse was still high. Overall, HCV-GT3 infection in patients with a history of DAA treatment failure poses challenges for the current antiviral treatments. In the present study, the pooled SVR rate of the four antiviral regimens for HCV-GT3 infection was 92.07%. The SVR rate of GLE+PIB was the highest (98.54%), and the treatment duration was the shortest (possibly eight weeks).

Clinical trials [37,44] reported that patients with the presence of baseline RASs (Y93H and A30K) in the NS5A gene had lower SVR rates, which was associated with decreased in vitro activity of DCV and VEL. In the ASTRAL-3 study [45], 84% SVR in the presence of Y93H compared to 97% in patients without Y93H was achieved from patients treated with SOF/VEL. However, in this meta-analysis only 6 articles completed RAVs test. It is interesting that all the 6 studies [8,12,13,17,20,34] draw a conclusion that RASs may be not associated with lower SVR rate. High SVR rates in patients completing therapy suggested that pretreatment RAS testing may not be necessary.

This meta-analysis has limitations. We think that no strong conclusions can be drawn due to high heterogeneity in four DAA regimens administration in real-world setting from 22 countries, as well as small numbers of patients treated with SOF+VEL+VOX and GLE+PIB. More studies are needed in the future in order to better analyze the antiviral effectiveness of DAAs in GT3 HCV patients in real-world studies.

5Conclusion

According to our meta-analysis of real-world studies, the antiviral effectiveness of treatment regimens for HCV-GT3 infection, including SOF+DCV±RBV, SOF+VEL±RBV, GLE+PIB, and SOF+VEL+VOX, was good. The SVR rate of GLE+PIB was higher, and the treatment duration was shorter than other regimens. Based on the findings, SOF+VEL+VOX can be used as a treatment regimen following DAA treatment failure. Also, a history of DAA treatment failure still poses challenges for current treatments.

Funding

This study was supported by the National Science and Technology Major Project of China under Gran [grant number 2018ZX10302-206-003-006]; the Capital’s Funds for Health Improvement and Research [grant number CFH 2020-1-2171 and CFH 2018-2-2173]; the Beijing Hospitals Authority Clinical Medicine Development of Special Funding [grant number XMLX201837]; the Digestive Medical Coordinated Development Center of Beijing Municipal Administration of Hospitals [grant number XXT26].

Conflict of interest

All authors had approved the final version of the manuscript for publication and agreed to be accountable for all aspects of the work. The authors have read the journal's policy on conflicts of interest and they declare that they have no competing interest.

Acknowledgement

Author Contributions: Study concept and design: Liwei Zhuang, and Huichun Xing; initial article screen: Shibo Ji, Yue Li, Ben Li, Ying Duan, Danying Cheng, Yu Zhang, Min Quan, Hong Zhao and Wei Li; finial article screen: Liwei Zhuang, and Yu Zhang; analysis and interpretation of data: Liwei Zhuang, Junnan Li, Yu Zhang, and Huichun Xing; drafting of the manuscript: Liwei Zhuang; critical revision of the manuscript for important intellectual content: Xiaomei Wang, Weini Ou, and Huichun Xing; statistical analysis: Liwei Zhuang, Junnan Li and Huichun Xing.

References
[1]
World Health Organization.
Hepatitis C fact sheet.
(2018),
[2]
E.J. Smolders, A.M.E. Jansen, P.G.J. Ter Horst, J. Rockstroh, D.J. Back, D.M. Burger.
Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations: A. 2019 Update.
Clin Pharmacokinet, 58 (2019), pp. 1237-1263
[3]
S. Sarwar, S. Tarique, A. Aleem, A.A. Khan.
Effect of adding daclatasvir in sofosbuvir-based therapy in genotype 3 hepatitis C: real-world experience in Pakistan.
Eur J Gastroenterol Hepatol, 31 (2019), pp. 1035-1039
[4]
A. Pariente, J.P. Arpurt, A.J. Remy, I. Rosa-Hezode, X. Causse, F. Heluwaert, et al.
Hepatitis C treatment with all-oral direct-acting antivirals: Effectiveness and tolerance in a multicenter, prospective, observational study from French general hospitals (APROVVIE, ANGH).
Presse Med, 48 (2019), pp. e101-e110
[5]
A. Mangia, G. Cenderello, M. Copetti, G. Verucchi, V. Piazzolla, C. Lorusso, et al.
SVR12 higher than 97% in GT3 cirrhotic patients with evidence of portal hypertension treated with SOF/VEL without ribavirin: A nation-wide cohort study.
Cells, (2019), pp. 8
[6]
L. Macken, W. Gelson, M. Priest, G. Abouda, S. Barclay, A. Fraser, et al.
Efficacy of direct-acting antivirals: UK real-world data from a well-characterised predominantly cirrhotic HCV cohort.
J Med Virol, 91 (2019), pp. 1979-1988
[7]
C.M.O. Lobato, L. Codes, G.F. Silva, A.F.M. Souza, H.S.M. Coelho, M.L.A. Pedroso, et al.
Direct antiviral therapy for treatment of hepatitis C: A real-world study from Brazil.
Ann Hepatol, 18 (2019), pp. 849-854
[8]
J. Llaneras, M. Riveiro-Barciela, S. Lens, M. Diago, A. Cachero, J. Garcia-Samaniego, et al.
Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs.
J Hepatol, 71 (2019), pp. 666-672
[9]
N.K.T. Hlaing, G. Nangia, K.T. Tun, S. Lin, M.Z. Maung, K.T. Myint, et al.
High sustained virologic response in genotypes 3 and 6 with generic NS5A inhibitor and sofosbuvir regimens in chronic HCV in myanmar.
J Viral Hepat, 26 (2019), pp. 1186-1199
[10]
Q. Han, X. Fan, X. Wang, Y. Wang, H. Deng, X. Zhang, et al.
High sustained virologic response rates of sofosbuvir-based regimens in Chinese patients with HCV genotype 3a infection in a real-world setting.
[11]
A. Goel, D.S. Bhadauria, A. Kaul, P. Verma, M. Mehrotra, A. Gupta, et al.
Daclatasvir and reduced-dose sofosbuvir: An effective and pangenotypic treatment for hepatitis C in patients with estimated glomerular filtration rate <30 mL/min.
Nephrology (Carlton), 24 (2019), pp. 316-321
[12]
E. Degasperi, A. Spinetti, A. Lombardi, S. Landonio, M.C. Rossi, L. Pasulo, et al.
Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous daa failure.
Journal of hepatology, 71 (2019), pp. 1106-1115
[13]
R. D’Ambrosio, L. Pasulo, M. Puoti, M. Vinci, M. Schiavini, S. Lazzaroni, et al.
Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C.
Journal of Hepatology, 70 (2019), pp. 379-387
[14]
Z. Butt, S.M.A. Shah.
Daclatasvir plus Sofosbuvir with or without ribavirin in patients with chronic Hepatitis C genotype 3a in Pakistani population - A real world experience.
Pak J Med Sci, 35 (2019), pp. 409-413
[15]
T. Berg, U. Naumann, A. Stoehr, C. Sick, C. John, G. Teuber, et al.
Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C infection: data from the German Hepatitis C-Registry.
Alimentary Pharmacology and Therapeutics, 49 (2019), pp. 1052-1059
[16]
P.S. Belperio, T.A. Shahoumian, T.P. Loomis, L.A. Mole, L.I. Backus.
Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3.
J Hepatol, 70 (2019), pp. 15-23
[17]
P.S. Belperio, T.A. Shahoumian, T.P. Loomis, L.I. Backus.
Real-world effectiveness of sofosbuvir/velpatasvir/voxilaprevir in 573 direct-acting antiviral experienced hepatitis C patients.
Journal of Viral Hepatitis, 26 (2019), pp. 980-990
[18]
A. Araujo, V. Valenzuela-Granados, A.B. Lopes, M.T. Michalczuk, A. Mantovani, M.R. Alvares-da-Silva.
Sofosbuvir-based antiviral therapy in patients with recurrent HCV infection after liver transplant: A real-life experience.
Ann Hepatol, 18 (2019), pp. 450-455
[19]
M.H. Wehmeyer, P. Ingiliz, S. Christensen, D. Hueppe, T. Lutz, K.G. Simon, et al.
Real-world effectiveness of sofosbuvir-based treatment regimens for chronic hepatitis C genotype 3 infection: Results from the multicenter German hepatitis C cohort (GECCO-03).
J Med Virol, 90 (2018), pp. 304-312
[20]
J. von Felden, J. Vermehren, P. Ingiliz, S. Mauss, T. Lutz, K.G. Simon, et al.
High efficacy of sofosbuvir/velpatasvir and impact of baseline resistance-associated substitutions in hepatitis C genotype 3 infection.
Alimentary Pharmacology and Therapeutics, 47 (2018), pp. 1288-1295
[21]
Y.C. Tao, R. Deng, M.L. Wang, D.D. Lv, M. Yuan, Y.H. Wang, et al.
Satisfactory virological response and fibrosis improvement of sofosbuvir-based regimens for Chinese patients with hepatitis C virus genotype 3 infection: results of a real-world cohort study.
[22]
M. Mucenic, A. Bandeira de Mello Brandao, C.A. Marroni, A. Medeiros Fleck Jr., M.L. Zanotelli, G. Kiss, et al.
Daclatasvir and Sofosbuvir With or Without Ribavirin in Liver Transplant Recipients: A Single-Center Real-World Study.
Transplant Proc, 50 (2018), pp. 769-771
[23]
C. Mínguez, M. García-Deltoro, J. Flores, M.J. Galindo, M. Montero, S. Reus, et al.
Interferon-free therapy for treating hepatitis C virus in difficult-to-treat HIV-coinfected patients.
[24]
V. Mehta, R. Mahajan, V. Midha, V. Narang, K. Kaur, A. Singh, et al.
Impact of Direct Acting Antiviral Therapy for Treatment of Hepatitis C Genotypes 1, 3 and 4: A Real Life Experience from India.
J Clin Exp Hepatol, 8 (2018), pp. 7-14
[25]
S. Marciano, L. Haddad, M.V. Reggiardo, M. Peralta, C. Vistarini, M. Marino, et al.
Effectiveness and safety of original and generic sofosbuvir for the treatment of chronic hepatitis C: A real world study.
J Med Virol, 90 (2018), pp. 951-958
[26]
S.G. Lim, W.W. Phyo, S.R. Shah, K.M. Win, S. Hamid, T. Piratvisuth, et al.
Findings from a large Asian chronic hepatitis C real-life study.
Journal of Viral Hepatitis, 25 (2018), pp. 1533-1542
[27]
P. Kwo, M.W. Fried, K.R. Reddy, C. Soldevila-Pico, S. Khemichian, J. Darling, et al.
Daclatasvir and sofosbuvir treatment of decompensated liver disease or post-liver transplant hepatitis C virus recurrence in patients with advanced liver disease/cirrhosis in a real-world cohort.
Hepatol Commun, 2 (2018), pp. 354-363
[28]
J.K. Rockstroh, P. Ingiliz, J. Petersen, M. Peck-Radosavljevic, T.M. Welzel, M. Van der Valk, et al.
Daclatasvir plus sofosbuvir, with or without ribavirin, in real-world patients with HIV-HCV coinfection and advanced liver disease.
Antivir Ther, 22 (2017), pp. 225-236
[29]
K. Lacombe, H. Fontaine, C. Dhiver, S. Metivier, E. Rosenthal, T. Antonini, et al.
Real-World Efficacy of Daclatasvir and Sofosbuvir, With and Without Ribavirin, in HIV/HCV Coinfected Patients With Advanced Liver Disease in a French Early Access Cohort.
J Acquir Immune Defic Syndr, 75 (2017), pp. 97-107
[30]
C. Hezode, P. Lebray, V. De Ledinghen, F. Zoulim, V. Di Martino, N. Boyer, et al.
Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme.
Liver Int, 37 (2017), pp. 1314-1324
[31]
O. Dalgard, O. Weiland, G. Noraberg, L. Karlsen, L. Heggelund, M. Farkkila, et al.
Sofosbuvir based treatment of chronic hepatitis C genotype 3 infections-A Scandinavian real-life study.
PLoS One, 12 (2017),
[32]
M. Cornberg, J. Petersen, A. Schober, S. Mauss, K.H. Boker, R. Link, et al.
Real-world use, effectiveness and safety of anti-viral treatment in chronic hepatitis C genotype 3 infection.
Aliment Pharmacol Ther, 45 (2017), pp. 688-700
[33]
E. Gray, A. O’Leary, C. Bergin, M. Cannon, G. Courtney, O. Crosbie, et al.
Effectiveness of interferon-free therapy for the treatment of HCV-patients with compensated cirrhosis treated through the Irish early access program.
Expert Review of Gastroenterology and Hepatology, 11 (2017), pp. 593-601
[34]
H. Cheinquer, H. Sette Jr., F.H. Wolff, A. de Araujo, S. Coelho-Borges, S.R.P. Soares, et al.
Treatment of Chronic HCV Infection with the New Direct Acting Antivirals (DAA): First Report of a Real World Experience in Southern Brazil.
Ann Hepatol, 16 (2017), pp. 727-733
[35]
S. Alonso, M. Riveiro-Barciela, I. Fernandez, D. Rincon, Y. Real, S. Llerena, et al.
Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort.
J Viral Hepat, 24 (2017), pp. 304-311
[36]
T.M. Welzel, J. Petersen, K. Herzer, P. Ferenci, M. Gschwantler, H. Wedemeyer, et al.
Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort.
Gut, 65 (2016), pp. 1861-1870
[37]
D.R. Nelson, J.N. Cooper, J.P. Lalezari, E. Lawitz, P.J. Pockros, N. Gitlin, et al.
All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study.
Hepatology, 61 (2015), pp. 1127-1135
[38]
S. Zeuzem, G.R. Foster, S. Wang, A. Asatryan, E. Gane, J.J. Feld, et al.
Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection.
N Engl J Med, 378 (2018), pp. 354-369
[39]
D. Wyles, F. Poordad, S. Wang, L. Alric, F. Felizarta, P.Y. Kwo, et al.
Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial.
Hepatology, 67 (2018), pp. 514-523
[40]
E. Gane, E. Lawitz, D. Pugatch, G. Papatheodoridis, N. Brau, A. Brown, et al.
Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment.
N Engl J Med, 377 (2017), pp. 1448-1455
[41]
J.K. Rockstroh, K. Lacombe, R.M. Viani, C. Orkin, D. Wyles, A.F. Luetkemeyer, et al.
Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study.
Clin Infect Dis, 67 (2018), pp. 1010-1017
[42]
I.M. Jacobson, E. Lawitz, E.J. Gane, B.E. Willems, P.J. Ruane, R.G. Nahass, et al.
Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials.
Gastroenterology, 153 (2017), pp. 113-122
[43]
M. Bourliere, S.C. Gordon, S.L. Flamm, C.L. Cooper, A. Ramji, M. Tong, et al.
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection.
N Engl J Med, 376 (2017), pp. 2134-2146
[44]
D. Hernandez, N. Zhou, J. Ueland, A. Monikowski, F. McPhee.
Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors.
J Clin Virol., 57 (2013), pp. 13-18
[45]
G.R. Foster, N. Afdhal, S.K. Roberts, N. Brau, E.J. Gane, S. Pianko, et al.
Sofosbuvir and velpatasvir for HCV genotpye 2 and 3 infection.
N Engl J Med., 373 (2015), pp. 2608-2617
Download PDF
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

Quizás le interese:
10.1016/j.aohep.2022.100685
No mostrar más